FDA pediatric advisory committee calls for "black box" warning on antidepressant drugs

Article

The Food and Drug Administration's Psychopharmacologic Drugs Committee and the newly-formed Pediatric Advisory Committee have called for a "black box" warning that selective serotonin reuptake inhibitor antidepressant drugs carry a risk of suicidal behavior in children.

In a joint action after a contentious and emotional public hearing last month, the Food and Drug Administration's Psychopharmacologic Drugs Committee and the newly-formed Pediatric Advisory Committee have called for a "black box" warning that selective serotonin reuptake inhibitor antidepressant drugs carry a risk of suicidal behavior in children. The vote was 15 to eight. Speaking for the majority, Chairman Wayne Goodman, MD, said the warning is worthwhile because it "raise[s] the threshold" for prescribing these drugs for children and adolescents. Opponents fear the warning will impede access to needed treatment for those who are at risk of suicide because of underlying depressive illness. The FDA is not required to follow the recommendations of advisory committees, but it usually does. The agency is expected to announce its decision within a few months. For background on this long-simmering controversy, see "Updates" in the July 2004 issue, available at http://www.contemporarypediatrics.com/

Related Videos
Screening for and treating the metatarsus adductus foot deformity |  Image Credit: UNFO md ltd
Wendy Ripple, MD
Wendy Ripple, MD
Courtney Nelson, MD
DB-OTO improved hearing to normal in child with profound genetic deafness | Image Credit: © Marija - © Marija - stock.adobe.com.
Carissa Baker-Smith
Perry Roy, MD
Perry Roy, MD | Image Credit: Carolina Attention Specialists
Angela Nash, PhD, APRN, CPNP-PC, PMHS | Image credit: UTHealth Houston
© 2024 MJH Life Sciences

All rights reserved.